Phase II Trial Investigates Stem Cells as Immunotherapy for Septic Shock

Septic shock is a life-threatening condition characterized by widespread inflammation and organ damage, leading to significant mortality and long-term morbidity for survivors. Pre-clinical research and a prior Phase I clinical trial (CISS) have suggested that mesenchymal stromal cells (MSCs) possess immunomodulatory properties, potentially enhancing pathogen clearance and promoting tissue repair. Despite promising initial safety data, the clinical efficacy of MSCs in human septic shock remains unconfirmed in a large-scale, randomized setting.

As this is a recruiting trial, no results are available yet. However, the study is designed to rigorously evaluate several key outcomes. The primary objective is to assess intermediate measures of clinical efficacy, aiming to quantify the therapeutic benefit of MSC treatment. Secondary outcomes will include a comprehensive analysis of biomarkers (molecular indicators of disease or treatment response), further validation of the safety profile of MSCs, various clinical outcome measures (e.g., organ function scores, length of hospital stay), and a detailed health economic analysis. The most critical aim of this Phase II trial is to determine if allogeneic umbilical cord-derived human mesenchymal stromal cells can significantly improve intermediate measures of clinical efficacy in patients suffering from septic shock compared to a placebo group, building on the Phase I safety findings.